Loading...
 
Back to the list
Mediterr J Rheumatol 2022;33(Suppl 1):115-25
Article Links
Molecular Mechanisms of New Bone Formation in Axial Spondyloarthritis
Kalliopi Klavdianou1, Anastasia Kanellou2, Dimitrios Daoussis3
Authors Information

1. Department of Rheumatology, "Asklepieion" General Hospital, Athens, Greece

2. Department of Anatomy-Histology-Embryology, Laboratory of Bone and Soft Tissue Studies, University of Patras Medical School, Patras, Greece

3. Department of Rheumatology, Patras University Hospital, University of Patras Medical School, Patras, Greece

Keywords: axial spondyloarthritis, ankylosing spondylitis, new bone formation, osteoblastogenesis, Wnt, Hedgehog, IL-17, TNF, serotonin
References
  1. Sieper J, Poddubnyy D. Axial spondyloarthritis. Vol. 390, The Lancet. Lancet Publishing Group; 2017. p. 73-84.
  2. Ritchlin C, Adamopoulos IE. Axial spondyloarthritis: New advances in diagnosis and management. Vol. 372, The BMJ. BMJ Publishing Group; 2021.
  3. van der HD, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008 Oct;58:3063-70.
  4. van der HD, Landewe R, Einstein S, Ory P, Vosse D, Ni L, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008 May;58:1324-31.
  5. Baraliakos X, Haibel H, Listing J, Sieper J, Braun J. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 2014;73(4).
  6. Dell’Accio F, De Bari C, El Tawil NMF, Barone F, Mitsiadis TA, O’Dowd J, et al. Activation of WNT and BMP signaling in adult human articular cartilage following mechanical injury. Arthritis Res Ther 2006;8(5):R139.
  7. Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell 2012 Jun;149(6):1192-205.
  8. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781-810.
  9. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009 Jul;17(1):9-26.
  10. Daoussis D, Andonopoulos AP, Liossis SN. Wnt Pathway and IL-17: Novel Regulators of Joint Remodeling in Rheumatic Diseases. Looking Beyond the RANK-RANKL-OPG Axis. Semin Rheum 2008 Dec 16;(1532-866X (Electronic)).
  11. Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, et al. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 2002 Jun;417(6889):664-7.
  12. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005 May;280(20):19883-7.
  13. Klavdianou K, Liossis S-N, Sakkas L, Daoussis D. The role of Dickkopf-1 in joint remodeling and fibrosis: A link connecting spondyloarthropathies and scleroderma? Semin Arthritis Rheum 2016 Aug 23;
  14. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002 May;346(20):1513-21.
  15. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001 Nov;107(4):513-23.
  16. Lefebvre V, Bhattaram P. Vertebrate skeletogenesis. Curr Top Dev Biol 2010;90:291-317.
  17. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13(2):156-63.
  18. Li X, Wang J, Zhan Z, Li S, Zheng Z, Wang T, et al. Inflammation Intensity-Dependent Expression of Osteoinductive Wnt Proteins Is Critical for Ectopic New Bone Formation in Ankylosing Spondylitis. Arthritis Rheumatol (Hoboken, NJ) 2018 Jul;70(7):1056-70.
  19. Uderhardt S, Diarra D, Katzenbeisser J, David J-P, Zwerina J, Richards W, et al. Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis 2010 Mar;69(3):592-7.
  20. Haynes KR, Pettit AR, Duan R, Tseng H-W, Glant TT, Brown MA, et al. Excessive bone formation in a mouse model of ankylosing spondylitis is associated with decreases in Wnt pathway inhibitors. Arthritis Res Ther 2012 Nov;14(6):R253.
  21. Haynes KR, Tseng H-W, Kneissel M, Glant TT, Brown MA, Thomas GP. Treatment of a mouse model of ankylosing spondylitis with exogenous sclerostin has no effect on disease progression. BMC Musculoskelet Disord 2015 Nov;16:368.
  22. Bougault C, Briolay A, Boutet M-A, Pilet P, Delplace S, Le Goff B, et al. Wnt5a is expressed in spondyloarthritis and exerts opposite effects on enthesis and bone in murine organ and cell cultures. Transl Res 2015 Dec;166(6):627-38.
  23. Lai N-S, Yu H-C, Chen H-C, Yu C-L, Huang H-B, Lu M-C. Aberrant expression of microRNAs in T cells from patients with ankylosing spondylitis contributes to the immunopathogenesis. Clin Exp Immunol 2013 Jul;173(1):47-57.
  24. Kapinas K, Kessler C, Ricks T, Gronowicz G, Delany AM. miR-29 modulates Wnt signaling in human osteoblasts through a positive feedback loop. J Biol Chem 2010 Aug;285(33):25221-31.
  25. Zhang F, Cao K, Du G, Zhang Q, Yin Z. miR-29a promotes osteoblast proliferation by downregulating DKK-1 expression and activating Wnt/β-catenin signaling pathway. Adv Clin Exp Med 2019 Oct;28(10):1293-300.
  26. Ma S, Wang D-D, Ma C-Y, Zhang Y-D. microRNA-96 promotes osteoblast differentiation and bone formation in ankylosing spondylitis mice through activating the Wnt signaling pathway by binding to SOST. J Cell Biochem 2019 Sep;120(9):15429-42.
  27. Daoussis D, Liossis SNC, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 2010;62(1):150-8.
  28. Nocturne G, Pavy S, Boudaoud S, Seror R, Goupille P, Chanson P, et al. Increase in dickkopf-1 serum level in recent spondyloarthritis. Data from the DESIR cohort. PLoS One 2015;10(8):1-16.
  29. Rubio Vargas R, Melguizo Madrid E, González Rodríguez C, Navarro Sarabia F, Dominguez Quesada C, Ariza Ariza R, et al. Association between serum dickkopf-1 levels and disease duration in axial spondyloarthritis. Reumatol Clin 2017;13(4):197-200.
  30. Zhang L, Ouyang H, Xie Z, Liang Z-H, Wu X-W. Serum DKK-1 level in the development of ankylosing spondylitis and rheumatic arthritis: a meta-analysis. Exp Mol Med 2016;48:e228.
  31. Zou Y, Yang X, Yuan S, Zhang P, Ye Y, Li Y. Downregulation of dickkopf-1 enhances the proliferation and osteogenic potential of fibroblasts isolated from ankylosing spondylitis patients via the Wnt/β-catenin signaling pathway in vitro. Connect Tissue Res 2016 Feb;1-12.
  32. Cortes A, Maksymowych WP, Wordsworth BP, Inman RD, Danoy P, Rahman P, et al. Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis. Ann Rheum Dis 2015;74(7):1387-93.
  33. Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009 Nov;60(11):3257-62.
  34. Klingberg E, Nurkkala M, Carlsten H, Forsblad-d’Elia H. Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis. J Rheumatol 2014 Jul;41(7):1349-56.
  35. Tsui FWL, Tsui HW, Las Heras F, Pritzker KPH, Inman RD. Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis. Ann Rheum Dis 2014 Oct;73(10):1873-9.
  36. Yucong Z, Lu L, Shengfa L, Yongliang Y, Ruguo S, Yikai L. Serum functional dickkopf-1 levels are inversely correlated with radiographic severity of ankylosing spondylitis. Clin Lab 2014;60(9):1527-31.
  37. Sakellariou GT, Iliopoulos A, Konsta M, Kenanidis E, Potoupnis M, Tsiridis E, et al. Serum levels of Dkk-1, sclerostin and VEGF in patients with ankylosing spondylitis and their association with smoking, and clinical, inflammatory and radiographic parameters. Joint Bone Spine 2017 May;84(3):309-15.
  38. Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel H, et al. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis 2012 Apr;71:572-4.
  39. Rademacher J, Tietz LM, Le L, Hartl A, Hermann K-GA, Sieper J, et al. Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis. Rheumatology (Oxford) 2019 Sep;58(9):1556-64.
  40. Yeremenko N, Zwerina K, Rigter G, Pots D, Fonseca JE, Zwerina J, et al. Brief Report: Tumor Necrosis Factor and Interleukin-6 Differentially Regulate Dkk-1 in the Inflamed Arthritic Joint. Arthritis Rheumatol 2015;67(8):2071-5.
  41. Osta B, Lavocat F, Eljaafari A, Miossec P. Effects of Interleukin-17A on Osteogenic Differentiation of Isolated Human Mesenchymal Stem Cells. Front Immunol 2014;5:425.
  42. Shah M, Maroof A, Gikas P, Mittal G, Keen R, Baeten D, et al. Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells. RMD Open 2020 Jul 28;6(2).
  43. Ruutu M, Thomas G, Steck R, Degli-Esposti MA, Zinkernagel MS, Alexander K, et al. β-glucan triggers spondylarthritis and Crohn’s disease-like ileitis in SKG mice. Arthritis Rheum 2012 Jul;64(7):2211-22.
  44. Lim D-H, Lee E-J, Kwon OC, Hong S, Lee C-K, Yoo B, et al. Effect of tumor necrosis factor inhibition on spinal inflammation and spinal ankylosis in SKG mice. Sci Rep 2019 Nov;9(1):18000.
  45. Benjamin M, Toumi H, Suzuki D, Hayashi K, McGonagle D. Evidence for a distinctive pattern of bone formation in enthesophytes. Ann Rheum Dis 2009 Jun;68(1468-2060 (Electronic)):1003-10.
  46. Rockel JS, Alman BA. Don’t hedge your bets: hedgehog signaling as a central mediator of endochondral bone development and cartilage diseases. J Orthop Res 2011 Jun;29:810-5.
  47. Long F, Zhang XM, Karp S, Yang Y, McMahon AP. Genetic manipulation of hedgehog signaling in the endochondral skeleton reveals a direct role in the regulation of chondrocyte proliferation. Development 2001 Dec;128:5099-108.
  48. St Jacques B, Hammerschmidt M, McMahon AP. Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev 1999 Aug 15;:2072-86.
  49. Lin AC, Seeto BL, Bartoszko JM, Khoury MA, Whetstone H, Ho L, et al. Modulating hedgehog signaling can attenuate the severity of osteoarthritis. Nat Med 2009 Dec;15:1421-5.
  50. Ruiz-Heiland G, Horn A, Zerr P, Hofstetter W, Baum W, Stock M, et al. Blockade of the hedgehog pathway inhibits osteophyte formation in arthritis. Ann Rheum Dis 2012;71(3):400-7.
  51. Dittmann K, Wuelling M, Uhmann A, Dullin C, Hahn H, Schweyer S, et al. Inactivation of patched1 in chondrocytes causes spinal fusion without inflammation. Arthritis Rheum 2014 Apr;66(4):831-40.
  52. Daoussis D, Filippopoulou A, Liossis SN, Sirinian C, Klavdianou K, Bouris P, et al. Anti-TNFalpha treatment decreases the previously increased serum Indian Hedgehog levels in patients with ankylosing spondylitis and affects the expression of functional Hedgehog pathway target genes. Semin Rheum 2015 Jun;44:646-51.
  53. Bliziotes M. Update in serotonin and bone. J Clin Endocrinol Metab 2010;95(9):4124-32.
  54. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med 2009 Jan;60:355-66.
  55. Gaspar P, Cases O, Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci 2003 Dec;4(12):1002-12.
  56. Bliziotes MM, Eshleman AJ, Zhang XW WK. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone 2001 Nov;29(5):477-86.
  57. Westbroek I, van der Plas A, de Rooij KE, Klein-Nulend J, Nijweide PJ. Expression of serotonin receptors in bone. J Biol Chem 2001 Aug;276(31):28961-8.
  58. Ducy P, Karsenty G. The two faces of serotonin in bone biology. J Cell Biol 2010;191(1):7-13.
  59. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schütz G, et al. Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum. Cell 2008;135(5):825-37.
  60. Yadav VK, Balaji S, Suresh PS, Liu XS, Lu X, Li Z, et al. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med 2010;16(3):308-12.
  61. Shi Z-C, Devasagayaraj A, Gu K, Jin H, Marinelli B, Samala L, et al. Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders. J Med Chem 2008 Jul;51(13):3684-7.
  62. Nam S-S, Lee JC, Kim HJ, Park J-W, Lee J-M, Suh J-Y, et al. Serotonin Inhibits Osteoblast Differentiation and Bone Regeneration in Rats. J Periodontol 2016 Apr;87(4):461-9.
  63. Long F1. When the gut talks to bone. Cell 2008;135(5):795-6.
  64. Karsenty G, Yadav VK. Regulation of bone mass by serotonin: molecular biology and therapeutic implications. Annu Rev Med 2011;62:323-31.
  65. Hanley HG, Stahl SM, Freedman DX. Hyperserotonemia and amine metabolites in autistic and retarded children. Arch Gen Psychiatry 1977 May;34(5):521-31.
  66. Hediger ML, England LJ, Molloy CA, Yu KF, Manning-Courtney P, Mills JL. Reduced bone cortical thickness in boys with autism or autism spectrum disorder. J Autism Dev Disord 2008 May;38(5):848-56.
  67. Mödder UI, Achenbach SJ, Amin S, Riggs BL, Melton LJ, Khosla S. Relation of serum serotonin levels to bone density and structural parameters in women. J Bone Miner Res 2010;25(2):415-22.
  68. Frost M, Andersen TE, Yadav V, Brixen K, Karsenty G, Kassem M. Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin. J Bone Miner Res 2010 Mar;25(3):673-5.
  69. Frost M, Andersen T, Gossiel F, Hansen S, Bollerslev J, van Hul W, et al. Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5. J Bone Miner Res 2011 Aug;26(8):1721-8.
  70. Ziere G, Dieleman JP, van der Cammen TJM, Hofman A, Pols HAP, Stricker BHC. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol 2008 Aug;28(4):411-7.
  71. Liu B1, Anderson G, Mittmann N, To T, Axcell T SN. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998;May 2;351(9112):1303-7.
  72. Klavdianou K, Liossis S-N, Papachristou DJ, Theocharis G, Sirinian C, Kottorou A, et al. Decreased Serotonin Levels and Serotonin-Mediated Osteoblastic Inhibitory Signaling in Patients With Ankylosing Spondylitis. J Bone Miner Res 2016 Mar;31(3):630-9.
  73. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103(9):1345-52.
  74. Kim KW, Kim HR, Kim BM, Cho M La, Lee SH. Th17 cytokines regulate osteoclastogenesis in rheumatoid arthritis. Am J Pathol 2015 Nov;185(11):3011-24.
  75. Chabaud M, Lubberts E, Joosten L, Berg W van den, Miossec P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001;3(3):1.
  76. Yago T, Nanke Y, Ichikawa N, Kobashigawa T, Mogi M, Kamatani N, et al. IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-α antibody: A novel mechanism of osteoclastogenesis by IL-17. J Cell Biochem 2009 Nov;108(4):947-55.
  77. Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJJ, Kolls JK, et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol 2003;170(Cii):2655-62.
  78. Adamopoulos IE, Chao C-C, Geissler R, Laface D, Blumenschein W, Iwakura Y, et al. Interleukin-17A upregulates receptor activator of NF-κB on osteoclast precursors. Arthritis Res Ther 2010 Feb;12(1):R29.
  79. Katz Y, Nadiv O, Beer Y. Interleukin-17 Enhances Tumor Necrosis Factor α-Induced Synthesis of Interleukins 1, 6, and 8 in Skin and Synovial Fibroblasts: A Possible Role as a “Fine-Tuning Cytokine” in Inflammation Processes. Arthritis Rheum 2001 Sep;44(9):2176-84.
  80. Kim Y-G, Park J-W, Lee J-M, Suh J-Y, Lee J-K, Chang B-S, et al. IL-17 inhibits osteoblast differentiation and bone regeneration in rat. Arch Oral Biol 2014;59:897-905.
  81. Zhang J-R, Pang D-D, Tong Q, Liu X, Su D-F, Dai S-M. Different Modulatory Effects of IL-17, IL-22, and IL-23 on Osteoblast Differentiation. Mediators Inflamm 2017;2017:5950395.
  82. Shaw AT, Maeda Y, Gravallese EM. IL-17A deficiency promotes periosteal bone formation in a model of inflammatory arthritis. Arthritis Res Ther 2016 May 10;18(1):104.
  83. Uluçkan Ö, Jimenez M, Karbach S, Jeschke A, Graña O, Keller J, et al. Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts. Sci Transl Med 2016 Mar 16;8(330):330ra37.
  84. Deselm CJ, Takahata Y, Warren J, Chappel JC, Khan T, Li X, et al. IL-17 mediates estrogen-deficient osteoporosis in an Act1-dependent manner. J Cell Biochem 2012 Sep;113(9):2895-902.
  85. Tyagi AM, Mansoori MN, Srivastava K, Khan MP, Kureel J, Dixit M, et al. Enhanced immunoprotective effects by anti-il-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-α antibodies. J Bone Miner Res 2014;29(9):1981-92.
  86. Huang H, Kim HJ, Chang EJ, Lee ZH, Hwang SJ, Kim HM, et al. IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: Implications for bone remodeling. Cell Death Differ 2009;16(10):1332-43.
  87. Sebastian AA, Kannan TP, Norazmi MN, Nurul AA. Interleukin-17A promotes osteogenic differentiation by increasing OPG/RANKL ratio in stem cells from human exfoliated deciduous teeth (SHED). J Tissue Eng Regen Med 2018;12(8).
  88. Croes M, Öner FC, van Neerven D, Sabir E, Kruyt MC, Blokhuis TJ, et al. Proinflammatory T cells and IL-17 stimulate osteoblast differentiation. Bone 2016 Mar;84:262-70.
  89. Ono T, Okamoto K, Nakashima T, Nitta T, Hori S, Iwakura Y, et al. IL-17-producing γδT cells enhance bone regeneration. Nat Commun 2016;7:1-9.
  90. Goswami J, Hernández-Santos N, Zuniga LA, Gaffen SL. A bone-protective role for IL-17 receptor signaling in ovariectomy-induced bone loss. Eur J Immunol 2009 Oct;39(10):2831-9.
  91. Osta B, Roux J-P, Lavocat F, Pierre M, Ndongo-Thiam N, Boivin G, et al. Differential effects of IL-17A and TNF-α on osteoblastic differentiation of isolated synoviocytes and on bone explants from arthritis patients. Front Immunol 2015 Apr 7;6:151.
  92. Jo S, Wang SE, Lee YL, Kang S, Lee B, Han J, et al. IL-17A induces osteoblast differentiation by activating JAK2/STAT3 in ankylosing spondylitis. Arthritis Res Ther 2018 Jun;20(1).
  93. van Tok MN, van Duivenvoorde LM, Kramer I, Ingold P, Pfister S, Roth L, et al. Interleukin-17A Inhibition Diminishes Inflammation and New Bone Formation in Experimental Spondyloarthritis. Arthritis Rheumatol 2019;71(4):612-25.
  94. Papagoras C, Chrysanthopoulou A, Mitsios A, Ntinopoulou M, Tsironidou V, Batsali AK, et al. Clinical Immunodeficiencies and autoimmunity IL-17A expressed on neutrophil extracellular traps promotes mesenchymal stem cell differentiation toward bone-forming cells in ankylosing spondylitis. Eur J Immunol 2021 2021;51:930-42.
  95. Van Mechelen M, Lories RJ. Microtrauma: No longer to be ignored in spondyloarthritis? Vol. 28, Current Opinion in Rheumatology. Lippincott Williams and Wilkins; 2016. p. 176-80.
  96. Jacques P, Lambrecht S, Verheugen E, Pauwels E, Kollias G, Armaka M, et al. Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann Rheum Dis 2014 Feb 1;73:437-45.
  97. Cambré I, Gaublomme D, Burssens A, Jacques P, Schryvers N, De Muynck A, et al. Mechanical strain determines the site-specific localization of inflammation and tissue damage in arthritis. Nat Commun 2018 Dec 1;9(1).
  98. Cambré I, Gaublomme D, Schryvers N, Lambrecht S, Lories R, Venken K, et al. Running promotes chronicity of arthritis by local modulation of complement activators and impairing T regulatory feedback loops. Ann Rheum Dis 2019 Jun 1;78(6):787-95.
  99. Ramiro S, Landewé R, Van Tubergen A, Boonen A, Stolwijk C, Dougados M, et al. Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: A longitudinal analysis. RMD Open 2015 Jan 1;1(1).
  100. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med 2017 Oct;377(15):1417-27.
  101. Iyer SP, Beck JT, Stewart AK, Shah J, Kelly KR, Isaacs R, et al. A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol 2014;167(3):366-75.
  102. Wall JA, Klempner SJ, Arend RC. The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer. Expert Opin Investig Drugs 2020 Jul;29(7):639-44.
  103. Molnar C, Scherer A, Baraliakos X, De Hooge M, Micheroli R, Exer P, et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis 2018;77:63-9.
  104. Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013 Oct;65:2645-54.
  105. Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 2017 Jun;76(6):1070-7.